- Home
- WASH vs CRVS Comparison
WASH vs CRVS Comparison
Compare WASH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WASH
- CRVS
- Stock Information
- Founded
- WASH 1800
- CRVS 2014
- Country
- WASH United States
- CRVS United States
- Employees
- WASH N/A
- CRVS N/A
- Industry
- WASH Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- WASH Finance
- CRVS Health Care
- Exchange
- WASH Nasdaq
- CRVS Nasdaq
- Market Cap
- WASH 541.1M
- CRVS 451.0M
- IPO Year
- WASH N/A
- CRVS 2016
- Fundamental
- Price
- WASH $38.33
- CRVS $8.19
- Analyst Decision
- WASH Hold
- CRVS Buy
- Analyst Count
- WASH 2
- CRVS 4
- Target Price
- WASH $34.00
- CRVS $12.83
- AVG Volume (30 Days)
- WASH 143.9K
- CRVS 1.1M
- Earning Date
- WASH 10-21-2024
- CRVS 11-12-2024
- Dividend Yield
- WASH 5.84%
- CRVS N/A
- EPS Growth
- WASH N/A
- CRVS N/A
- EPS
- WASH 2.67
- CRVS N/A
- Revenue
- WASH $188,967,000.00
- CRVS N/A
- Revenue This Year
- WASH N/A
- CRVS N/A
- Revenue Next Year
- WASH $6.82
- CRVS N/A
- P/E Ratio
- WASH $14.36
- CRVS N/A
- Revenue Growth
- WASH N/A
- CRVS N/A
- 52 Week Low
- WASH $24.11
- CRVS $1.30
- 52 Week High
- WASH $40.59
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- WASH 60.71
- CRVS 51.74
- Support Level
- WASH $33.47
- CRVS $8.67
- Resistance Level
- WASH $40.59
- CRVS $10.00
- Average True Range (ATR)
- WASH 1.25
- CRVS 0.84
- MACD
- WASH 0.21
- CRVS -0.18
- Stochastic Oscillator
- WASH 68.26
- CRVS 18.10
About WASH Washington Trust Bancorp Inc.
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates. The bank generates a majority of its revenue from the Commercial Banking segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).